论文部分内容阅读
目的探究喘可治注射液辅助治疗非小细胞肺癌的临床疗效及对T淋巴细胞亚群的影响。方法选择2010年7月—2014年9月在新疆维吾尔自治区胸科医院接受治疗的102例非小细胞肺癌患者,采用随机数字表法将患者分为对照组和观察组,每组51例。对照组患者采用GP化疗方案(顺铂+吉西他滨)治疗,观察组在对照组治疗基础上联合喘可治注射液辅助治疗。比较两组患者临床疗效及毒副作用,治疗前后T淋巴细胞亚群(CD+3细胞分数、CD+4细胞分数、CD+8细胞分数以及CD+4/CD+8细胞比值)、QLQ-C30量表评分(主要包括社会功能、情绪功能、躯体功能以及整体生活质量4个方面)。结果观察组患者临床疗效优于对照组(u=2.534,P=0.011)。治疗前两组患者CD+3细胞分数、CD+4细胞分数、CD+8细胞分数、CD+4/CD+8细胞比值比较,差异无统计学意义(P>0.05);治疗后观察组患者CD+3细胞分数、CD+4细胞分数、CD+4/CD+8细胞比值均高于对照组(P<0.01)。治疗前两组患者社会功能、情绪功能、躯体功能以及整体生活质量评分比较,差异无统计学意义(P>0.05);治疗后观察组患者社会功能、情绪功能、躯体功能以及整体生活质量评分均高于对照组(P<0.01)。观察组患者白细胞计数(WBC)减少、血小板计数(PLT)减少、血红蛋白(HGB)水平降低及恶心呕吐发生率均低于对照组(P<0.05)。结论喘可治注射液辅助治疗非小细胞肺癌的临床疗效确切,能有效提高患者免疫功能,改善患者生活质量,且毒副作用较少。
Objective To investigate the clinical efficacy of Chuankezhi injection in the adjuvant treatment of non-small cell lung cancer and its effect on T lymphocyte subsets. Methods From July 2010 to September 2014, 102 patients with non-small cell lung cancer were treated in the Thoracic Hospital of Xinjiang Uygur Autonomous Region. The patients were divided into control group and observation group with 51 cases in each group by random number table. Patients in the control group were treated with GP chemotherapy (cisplatin + gemcitabine). The observation group was treated with the combination of Chuankezhi injection on the basis of the control group. The clinical efficacy and side effects of the two groups of patients were compared. T lymphocyte subsets (CD + 3 cell fraction, CD 4 cell fraction, CD 8 cell fraction and CD 4 / CD 8 cell ratio) before and after treatment, QLQ-C30 Scale (mainly including social function, emotional function, physical function and overall quality of life in four aspects). Results The clinical efficacy of the observation group was better than that of the control group (u = 2.534, P = 0.011). The difference of CD + 3 cell fraction, CD + 4 cell fraction, CD + 8 cell fraction and CD + 4 / CD + 8 cell ratio in the two groups before treatment was not statistically significant (P> 0.05) The percentage of CD + 3 cells, CD + 4 cells and CD + 4 / CD + 8 cells were higher than that of the control group (P <0.01). There was no significant difference in social function, emotional function, physical function and overall quality of life between the two groups before treatment (P> 0.05). After treatment, social function, emotional function, body function and overall quality of life scores Higher than the control group (P <0.01). The WBC, PLT, HGB, and nausea and vomit in the observation group were lower than those in the control group (P <0.05). Conclusion Chuankezhi injection is an effective adjuvant therapy for non-small cell lung cancer, which can effectively improve the immune function and improve the quality of life of patients with less toxic and side effects.